PanTera has signed an agreement with Bayer for the supply of actinium-225 starting in the second half of 2024.
PanTera is the Belgian joint venture created by Ion Beam Applications (IBA) and SCK CEN to secure large-scale production of alpha-emitting radioisotopes.
The agreement with Bayer is the first agreement with a major drug developer, PanTera said. The company plans to work on increasing access to actinium-225 for clinical trials, as well as on the development of a large-scale production facility to address growing global demand.
